Such a cytokine window is hypothesized to facilitate dosing for maximum killing potency within a range focused on safety (little to no IFNγ release) to that focused on IFNγ’s anti-tumor properties, which can be modulated at both an inter-patient and intra-patient basis depending on tolerability. This evidence concerns the gene IFNG and neoplasm.